DR. DANIEL EINHORN, M.D.
Osteopathic Medicine at Genesee Ave, La Jolla, CA
License number
California G52088
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
2
9850 Genesee Ave SUITE 415, La Jolla, CA 92037
8851 Center Dr SUITE 404, La Mesa, CA 91942
8851 Center Dr SUITE 404, La Mesa, CA 91942
Phone
(858) 622-7200
(619) 463-1293
(619) 463-1293
Organization information
See more information about DANIEL EINHORN at bizstanding.comDaniel Einhorn MD
9850 Genesee Ave, La Jolla, CA 92037
Industry:
Medical Doctor's Office
Phone:
(858) 622-7200 (Phone)
Physician Assistants:
Daniel Einhorn (Medical Doctor),Christopher E. Sadler (Physician Assistant)
Professional information
Daniel Einhorn, La Jolla CA
Specialties:
Endocrinologist
Address:
9850 Genesee Ave, La Jolla, CA 92037
8851 Center Dr, La Mesa, CA 91942
15725 Pomerado Rd, Poway, CA 92064
8851 Center Dr, La Mesa, CA 91942
15725 Pomerado Rd, Poway, CA 92064
Education:
Tufts University, School of Medicine - Doctor of Medicine*
Beth Israel Deaconess Medical Center - Fellowship - Endocrinology*
Beth Israel Deaconess Medical Center - Residency - Internal Medicine*
Beth Israel Deaconess Medical Center - Residency - Psychiatry*
Beth Israel Deaconess Medical Center - Fellowship - Endocrinology*
Beth Israel Deaconess Medical Center - Residency - Internal Medicine*
Beth Israel Deaconess Medical Center - Residency - Psychiatry*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)*
Dr. Daniel Einhorn, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Diabetes & Endocrine Associates
9850 Genesee Ave STE 415, La Jolla 92037
(858) 622-7200 (Phone)
9850 Genesee Ave STE 415, La Jolla 92037
(858) 622-7200 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1983, Internal Medicine, 1981
Awards:
Healthgrades Honor Roll
Languages:
English, French
Hospitals:
Diabetes & Endocrine Associates
9850 Genesee Ave STE 415, La Jolla 92037
Palomar Medical Center
555 East Valley Pkwy, Escondido 92025
Scripps Memorial Hospital Encinitas
354 Santa Fe Dr, Encinitas 92024
Sharp Grossmont Hospital
5555 Grossmont Center Dr, La Mesa 91942
9850 Genesee Ave STE 415, La Jolla 92037
Palomar Medical Center
555 East Valley Pkwy, Escondido 92025
Scripps Memorial Hospital Encinitas
354 Santa Fe Dr, Encinitas 92024
Sharp Grossmont Hospital
5555 Grossmont Center Dr, La Mesa 91942
Education:
Medical School
Tufts University
Graduated: 1977
Beth Israel Deaconess Medical Center
Tufts University
Graduated: 1977
Beth Israel Deaconess Medical Center
Treatment Of Insulin Resistance/Metabolic Syndrome To Alleviate The Risks Of Dementia
US Patent:
2011029, Dec 1, 2011
Filed:
Aug 8, 2011
Appl. No.:
13/205534
Inventors:
Stuart A. LIPTON - Rancho Santa Fe CA, US
Daniel EINHORN - La Jolla CA, US
Daniel EINHORN - La Jolla CA, US
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE - La Jolla CA
International Classification:
A61K 38/19, A61K 38/22, A61K 31/137, A61K 31/13, A61K 31/5685, A61B 5/00, A61K 31/64, A61K 31/155, A61K 31/426, A61K 31/5585, A61P 25/00, A61P 3/08, A61K 38/28, A61K 31/455
US Classification:
424 851, 514 59, 514 68, 514654, 514611, 514178, 514356, 514592, 514635, 514369, 514469, 600301
Abstract:
This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with β-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.
Treatment Of Insulin Resistance/Metabolic Syndrome To Alleviate The Risks Of Dementia
US Patent:
2009008, Apr 2, 2009
Filed:
May 10, 2005
Appl. No.:
11/569063
Inventors:
Stuart A. Lipton - Rancho Santa Fe CA, US
Daniel Einhorn - La Jolla CA, US
Daniel Einhorn - La Jolla CA, US
Assignee:
Burnham Institute For Medical Research - La Jolla CA
International Classification:
A61K 38/28, A61K 38/02, A61K 31/155, A61K 31/365, A61K 38/30, A61K 31/439, A61K 31/13, A61K 31/04, G06F 19/00
US Classification:
514 3, 514 2, 514635, 514449, 514 12, 514299, 514662, 514742, 702 19
Abstract:
This invention relates to Applicant's discovery that Metabolic Syndrome, a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with β-amyloid protein for the IDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.